ABIVAX Société Anonyme Management

Management criteria checks 1/4

ABIVAX Société Anonyme's CEO is Marc M. de Garidel, appointed in May 2023, has a tenure of less than a year. directly owns 0.061% of the company’s shares, worth €366.57K. The average tenure of the management team and the board of directors is 0.5 years and 4.8 years respectively.

Key information

Marc M. de Garidel

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.06%
Management average tenure	less than a year
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO

Marc M. de Garidel (65 yo)

less than a year

Tenure

Mr. Marc M. P. de Garidel, M.B.A., serves as CEO & Interim Chair of Board at ABIVAX Société Anonyme since May 5, 2023. He has been the Chief Executive Officer of CinCor Pharma, Inc. since July 2021 and has...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Philippe Pouletty	Founder & Director	no data	no data	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	no data	0.061% € 366.6k
Didier Blondel	EVP, CFO & Board Secretary	6.9yrs	no data	0.00060% € 3.6k
Didier Scherrer	Chief Scientific Officer	less than a year	no data	0.057% € 343.8k
Patrick Malloy	Senior Vice President of Investor Relations	less than a year	no data	no data
Ida Hatoum	Chief People Officer	less than a year	no data	no data
Pierre Courteille	Chief Business Officer	no data	no data	0% € 0
Jérôme Denis	Executive Vice President of Process Development & Manufacturing	less than a year	no data	no data
Sheldon Sloan	Chief Medical Officer	less than a year	no data	no data
Michael Ferguson	Chief Commercial Officer	less than a year	no data	no data

0.5yrs

Average Tenure

60yo

Average Age

Experienced Management: ABVXp's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Philippe Pouletty	Founder & Director	9yrs	no data	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	no data	0.061% € 366.6k
Christian Brechot	Member of Scientific Advisory Board	6.2yrs	no data	no data
Christian Trepo	Member of Scientific Advisory Board	no data	no data	no data
Lawrence Stanberry	Member of Scientific Advisory Board	no data	no data	no data
Troy Ignelzi	Independent Director	less than a year	no data	no data
Christoph Huber	Member of Scientific Advisory Board	no data	no data	no data
Claude Bertrand	Member of Scientific Advisory Board	4.2yrs	€4.94k	no data
Luc Teyton	Member of Scientific Advisory Board	no data	no data	no data
June Lee	Independent Director	less than a year	no data	no data
Corinna Bonsen-Thomas	Independent Non-Executive Director	6.5yrs	€22.89k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	5.5yrs	no data	no data

4.8yrs

Average Tenure

64.5yo

Average Age

Experienced Board: ABVXp's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/12/06 09:44
End of Day Share Price	2023/09/08 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ABIVAX Société Anonyme is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eric Le Berrigaud	Bryan Garnier & Co
Oscar Haffen Lamm	Bryan Garnier & Co
Julian Harrison	BTIG

ABIVAX Société Anonyme Management

Management criteria checks 1/4

Key information

Recent management updates

Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

Recent updates

Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources